Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial

Journal of Clinical Oncology

Volumn 18, Issue 7, 2000, Pages 1458-1464

  Jeremic, Branislav ^a   Shibamoto, Yuta ^a   Milicic, Biljana ^a   Nikolic, Nebojsa ^a   Dagovic, Aleksandar ^a   Aleksandrovic, Jasna ^a   Vaskovic, Zeljko ^a   Tadic, Ljiljana ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGITIS; FEMALE; HEAD AND NECK CANCER; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; XEROSTOMIA;

EID: 0034034509     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.7.1458     Document Type: Article

References (44)

1. Million RR, Cassisi NJ: Management of head and neck cancer: A multidisciplinary approach. Philadelphia, PA, JB Lippincott, 1994
2. Wang CC, Blitzer PH, Suit HD: Twice-a-day radiation therapy for cancer of the head and neck. Cancer 55:2100-2104, 1985
3. Cox JD, Pajak TF, Marcial VA, et al: Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: Preliminary report of Radiation Therapy Oncology Group, Protocol 83-13. Int J Radiat Oncol Biol Phys 18:515-521, 1990
4. Ang KK, Peters LJ, Weber RS, et al: Concomitant boost radiotherapy schedule in the treatment of carcinoma of the oropharynx and nasopharynx. Int J Radiat Oncol Biol Phys 19:1339-1345, 1990
5. Dische S, Saunders M, Barrett A, et al: A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck. Radiother Oncol 44:123-136, 1997
6. Al-Sarraf M, Pajak TF, Marcial VA, et al: Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck: An RTOG study. Cancer 59:259-265, 1987
7. Tobias JS, Smith BJ, Blackman G, et al: Concurrent daily cisplatin and radiotherapy in locally advanced squamous carcinoma of the head and neck and bronchus. Radiother Oncol 9:263-268, 1987
8. Browman GP, Cripps C, Hodson DI, et al: Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 12:2648-2653, 1994
9. Withers HR: Biologic basis for altered fractionated schemes. Cancer 55:2086-2095, 1985
10. Withers HR: Inherent acceleration of tumor dose-rate in hyperfractionated regimens. Int J Radiat Oncol Biol Phys 14:400, 1988 (letter)
11. Withers HR, Peters LJ: Biological aspects of radiation therapy, in Fletcher GH (ed): Textbook of Radiotherapy (ed 3). Philadelphia, PA, Lea and Febiger, 1980, p 103
12. Marcial VA, Pajak TF, Chang C, et al: Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: Preliminary report by the Radiation Therapy Oncology Group (RTOG). Int J Radiat Oncol Biol Phys 13:41-47, 1987
13. Datta NR, Choudhry AD, Gupta S, et al: Twice a day versus once a day radiation therapy in head and neck cancer. Int J Radiat Oncol Biol Phys 17:132-133, 1989 (suppl 1) (abstr)
14. Sanchiz F, Milla A, Torner J, et al: Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 19:1347-1350, 1990
15. Pinto LHJ, Canary PCV, Araujo CM, et al: Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 21:557-562, 1991
16. Horiot JC, LeFur R, N'Guyen T, et al: Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25:231-241, 1992
17. Head and Neck Contracts Program: Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Cancer 60:301-311, 1987
18. Vokes EE, Weichelsbaum RR, Lipman SM, et al: Head and neck cancer. N Engl J Med 328:184-193, 1993
19. Marcial VA, Pajak TF, Mohiuddin M, et al: Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck: Long term results of the Radiation Therapy Oncology Study 81-17. Cancer 66:1866-1868, 1990
20. Al-Sarraf M, LeBlanc M. Giri PGS, et al: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099. J Clin Oncol 16:1310-1317, 1998
21. Jeremic B, Shibamoto Y, Stanisavljevic B, et al: Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: A prospective randomized trial. Radiother Oncol 43:29-37, 1997
22. Dewitt L: Combined treatment of radiation and cis-diamminedichloroplatinum (II): A review of experimental and clinical data. Int J Radiat Oncol Biol Phys 13:403-426, 1987
23. Fu KK, Philips TL: Biologic rationale of combined radiotherapy and chemotherapy. Hematol Oncol Clin North Am 5:725-736, 1991
24. Forastiere AA, Belliveau JF, Goren MP, et al: Pharmakokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cisdiamminedichloroplatinum (II) in head and neck cancer patients. Cancer Res 48:3869-3874, 1988
25. Schwahofer JH, Croojimans RP, Hoogenhout J, et al: Effectiveness in inhibition of recovery of cell recovery of cell survival by cisplatin and carboplatin: Influence of treatment sequence. Int J Radiat Oncol Biol Phys 20:1235-1241, 1991
26. Skov K, MacPhail S: Interaction of platinum drugs with clinically relevant x-ray doses in mammalian cells: A comparison of cisplatin, carboplatin, iproplatin, and tetraplatin. Int J Radiat Oncol Biol Phys 20:221-225, 1991
27. Cox JD, Stetz JA, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for the Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341-1346, 1995
28. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
29. Freedman LS: Tables of the number of patients required in a clinical trial using the log rank test. Stat Med 1:121-130. 1982
30. Bartelink H, Kallman RF, Rapacchieta D, et al: Therapeutic enhancement in mice by clinically relevant dose and fractionation schedules of cis-diamminedichloroplatinum (II) and irradiation. Radiother Oncol 6:61-74, 1986
31. Jeremic B, Shibamoto Y, Acimovic L, et al: Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer. J Clin Oncol 14:1065-1070, 1996
32. Schaake-Konig C, van der Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530, 1992
33. Pinnaro P, Cercato MC, Giannerelli D, et al: A randomized phase II study comparing sequential versus simultaneous chemoradiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck. Ann Oncol 5:513-520, 1994
34. Fountzilas G, Skarlos D, Kosmidis P, et al: Radiation therapy and concurrent cisplatin administration in locally advanced head and neck cancer: A Hellenic co-operative oncology group study. Acta Oncol 33:825-830, 1994
35. Suit HD: Potential for improving survival rates for the cancer patient by increasing the efficacy of treatment of the primary lesion. Cancer 50:1227-1234, 1982
36. Suit HD, Westgate SJ: Impact of improved local control on survival. Int J Radiat Oncol Biol Phys 12:453-458, 1986
37. Suit HD: The scope of the problem of primary tumor control. Cancer 61:2141-2147, 1988
38. Suit HD: Local control and patient survival. Int J Radiat Oncol Biol Phys 23:653-660, 1992
39. Sailer SL, Weissler MC, Melin SA, et al: Toxicity and preliminary results from a trial of hyperfractionated radiation with or without simultaneous 5-fluorouracil-cisplatin in advanced head and neck carcinoma. Semin Radiat Oncol 2:38-40, 1992
40. Wendt TG, Grabenbauer GG, Rodel CM, et al: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. I Clin Oncol 16:1318-1324, 1998
41. Brizel DM, Albers ME, Fisher SR, et al: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798-1804, 1998
42. Huguenin P, Glanzmann C, Taussky D, et al: Hyperfractionated radiotherapy and simultaneous cisplatin for stage-III and -IV carcinomas of the head and neck: Long-term results including functional outcome. Strahlenther Onkol 174:397-402, 1998
43. Vokes EE, Mick R. Kies MS, et al: Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol 14:1663-1671, 1996
44. Robins KT, Kumar P, Regine WF, et al: Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: The Memphis experience. Int J Radiat Oncol Biol Phys 38:263-271, 1997